Stilla is exhibiting at the 3rd ACTC in Rhodes
4th-7th of October 2017, Rhodes (Greece)
3rd International Symposium ACTC – Advances in Circulating Tumour Cells :
Liquid Biopsy in Clinical Practice
4th-7th of October 2017
From October 4th to the 7th, Stilla Technologies participated to the 3rd ACTC (Advances in Circulating Tumor Cells) in Rhodes (Greece), represented by Laura Cavé (Sales Application Specialist) and Larry Ba (Key Account Manager).
The event was organized by Evi Lianidou (University of Athens), Klaus Pantel (University Medical Center, Hamburg) and The Hellenic Society of Tumor Biomarkers & Liquid Biopsies.
This International Symposium focused on the potential of Liquid Biopsies into the Clinical Practice field gathering both basic and clinical researchers as well as industrials from the clinical and pharmaceutical fields.
More than 300 researchers presented their studies and last advancements in applications such as circulating tumor cells (CTCs), disseminated tumor cells (DTCs), circulating tumor DNA (ctDNA), and miRNAs.
In fact, liquid biopsy is a non-invasive method commonly used for those type of applications, allowing thereafter diseases monitoring, drug and diagnostics development, the monitoring of targeted therapy, the identification of resistance mutations, prognosis etc.
Some studies were focused more specifically on single cell analysis, DNA methylation and whole genome amplification methods in different types of cancer (brain, breast, colorectal, prostate, lung and ovarian cancer as well as melanomas and carcinomas).
Moreover, different microfluidic tools and devices were used in the studies presented, confirming the need for Stilla Technologies to present the microfluidic Sapphire chip.
Stilla Technologies being active in the liquid biopsy field, it was a pleasure for us to meet and discuss new opportunities with researchers and industrials.